CLINICAL SIGNIFICANCE OF OSTEOBLAST PRECURSORS AND OSTEOCLAST PRECURSORS IN EARLIER DIAGNOSIS AND MONITORING OF MYELOMA BONE DISEASE
(Abstract release date: 05/19/16)
EHA Library. Fu R. 06/09/16; 134865; PB1965
Dr. Rong Fu
Contributions
Contributions
Abstract
Abstract: PB1965
Type: Publication Only
Background
Multiple myeloma (MM) is a kind of plasma malignant tumor. Myeloma bone disease (MBD) is a most common complication of MM, with up to 80% of them developing osteolytic lesions.The primary diagnostic procedure for the detection of bone involvement in MM is conventional radiography. Limited sensitivity was an important disadvantage of conventional X-ray in MBD.
Aims
To find more sensitive markers to diagnose bone disease earlier and evaluate the effect of therapy.
Methods
we detected circulating osteoclast precursors (OCPs) and osteoblast precursors (OBPs) by flow cytometry, comparing with special biochemical markers, such as tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), carboxy-terminal cross-linking telopeptide of type I collagen (CTX), osteocalcin (OCN) and procollagen I amino-terminal propeptide (PINP).
Results
The results showed that circulating OBPs in the newly diagnosed MM patients significantly decreased compared with the normal controls (7.14% VS 12.82%, P=0.045). While circulating OCPs in the newly diagnosed patients and remission patients were significantly increased than the normal controls (2.46% VS 0.17%, P=0.000; 1.87% VS 0.17%, P=0.000, respectively). According to X-ray, newly diagnosed patients were divided into stage A and B (without and with osteolytic lesions). Compared with the normal controls, circulating OBPs in stage A and B reduced (12.82% VS 7.47%, P=0.041; 12.82% VS 7.14%, P=0.010, respectively), while circulating OCPs elevated (0.17% VS 2.71%, P=0.001; 0.17% VS 2.37%, P=0.010, respectively). The levels of TRACP-5b and CTX in the newly diagnosed patients were higher than the normal controls (P=0.014, P=0.037) and remission patients (P=0.025, P=0.003), and they were significantly higher in stage B than the normal controls (P=0.015, P=0.002). However, PINP and OCN levels had no significantly changes in different stages.
Conclusion
In conclusion, abnormal circulating OBPs and OCPs were found earlier before X-ray in MM and still existed in remission patients, indicating that they maybe novel predictive markers for early diagnosing and monitoring bone disease.
Session topic: E-poster
Keyword(s): Myeloma, Osteoblast, Osteoclast
Type: Publication Only
Background
Multiple myeloma (MM) is a kind of plasma malignant tumor. Myeloma bone disease (MBD) is a most common complication of MM, with up to 80% of them developing osteolytic lesions.The primary diagnostic procedure for the detection of bone involvement in MM is conventional radiography. Limited sensitivity was an important disadvantage of conventional X-ray in MBD.
Aims
To find more sensitive markers to diagnose bone disease earlier and evaluate the effect of therapy.
Methods
we detected circulating osteoclast precursors (OCPs) and osteoblast precursors (OBPs) by flow cytometry, comparing with special biochemical markers, such as tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), carboxy-terminal cross-linking telopeptide of type I collagen (CTX), osteocalcin (OCN) and procollagen I amino-terminal propeptide (PINP).
Results
The results showed that circulating OBPs in the newly diagnosed MM patients significantly decreased compared with the normal controls (7.14% VS 12.82%, P=0.045). While circulating OCPs in the newly diagnosed patients and remission patients were significantly increased than the normal controls (2.46% VS 0.17%, P=0.000; 1.87% VS 0.17%, P=0.000, respectively). According to X-ray, newly diagnosed patients were divided into stage A and B (without and with osteolytic lesions). Compared with the normal controls, circulating OBPs in stage A and B reduced (12.82% VS 7.47%, P=0.041; 12.82% VS 7.14%, P=0.010, respectively), while circulating OCPs elevated (0.17% VS 2.71%, P=0.001; 0.17% VS 2.37%, P=0.010, respectively). The levels of TRACP-5b and CTX in the newly diagnosed patients were higher than the normal controls (P=0.014, P=0.037) and remission patients (P=0.025, P=0.003), and they were significantly higher in stage B than the normal controls (P=0.015, P=0.002). However, PINP and OCN levels had no significantly changes in different stages.
Conclusion
In conclusion, abnormal circulating OBPs and OCPs were found earlier before X-ray in MM and still existed in remission patients, indicating that they maybe novel predictive markers for early diagnosing and monitoring bone disease.
Session topic: E-poster
Keyword(s): Myeloma, Osteoblast, Osteoclast
Abstract: PB1965
Type: Publication Only
Background
Multiple myeloma (MM) is a kind of plasma malignant tumor. Myeloma bone disease (MBD) is a most common complication of MM, with up to 80% of them developing osteolytic lesions.The primary diagnostic procedure for the detection of bone involvement in MM is conventional radiography. Limited sensitivity was an important disadvantage of conventional X-ray in MBD.
Aims
To find more sensitive markers to diagnose bone disease earlier and evaluate the effect of therapy.
Methods
we detected circulating osteoclast precursors (OCPs) and osteoblast precursors (OBPs) by flow cytometry, comparing with special biochemical markers, such as tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), carboxy-terminal cross-linking telopeptide of type I collagen (CTX), osteocalcin (OCN) and procollagen I amino-terminal propeptide (PINP).
Results
The results showed that circulating OBPs in the newly diagnosed MM patients significantly decreased compared with the normal controls (7.14% VS 12.82%, P=0.045). While circulating OCPs in the newly diagnosed patients and remission patients were significantly increased than the normal controls (2.46% VS 0.17%, P=0.000; 1.87% VS 0.17%, P=0.000, respectively). According to X-ray, newly diagnosed patients were divided into stage A and B (without and with osteolytic lesions). Compared with the normal controls, circulating OBPs in stage A and B reduced (12.82% VS 7.47%, P=0.041; 12.82% VS 7.14%, P=0.010, respectively), while circulating OCPs elevated (0.17% VS 2.71%, P=0.001; 0.17% VS 2.37%, P=0.010, respectively). The levels of TRACP-5b and CTX in the newly diagnosed patients were higher than the normal controls (P=0.014, P=0.037) and remission patients (P=0.025, P=0.003), and they were significantly higher in stage B than the normal controls (P=0.015, P=0.002). However, PINP and OCN levels had no significantly changes in different stages.
Conclusion
In conclusion, abnormal circulating OBPs and OCPs were found earlier before X-ray in MM and still existed in remission patients, indicating that they maybe novel predictive markers for early diagnosing and monitoring bone disease.
Session topic: E-poster
Keyword(s): Myeloma, Osteoblast, Osteoclast
Type: Publication Only
Background
Multiple myeloma (MM) is a kind of plasma malignant tumor. Myeloma bone disease (MBD) is a most common complication of MM, with up to 80% of them developing osteolytic lesions.The primary diagnostic procedure for the detection of bone involvement in MM is conventional radiography. Limited sensitivity was an important disadvantage of conventional X-ray in MBD.
Aims
To find more sensitive markers to diagnose bone disease earlier and evaluate the effect of therapy.
Methods
we detected circulating osteoclast precursors (OCPs) and osteoblast precursors (OBPs) by flow cytometry, comparing with special biochemical markers, such as tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), carboxy-terminal cross-linking telopeptide of type I collagen (CTX), osteocalcin (OCN) and procollagen I amino-terminal propeptide (PINP).
Results
The results showed that circulating OBPs in the newly diagnosed MM patients significantly decreased compared with the normal controls (7.14% VS 12.82%, P=0.045). While circulating OCPs in the newly diagnosed patients and remission patients were significantly increased than the normal controls (2.46% VS 0.17%, P=0.000; 1.87% VS 0.17%, P=0.000, respectively). According to X-ray, newly diagnosed patients were divided into stage A and B (without and with osteolytic lesions). Compared with the normal controls, circulating OBPs in stage A and B reduced (12.82% VS 7.47%, P=0.041; 12.82% VS 7.14%, P=0.010, respectively), while circulating OCPs elevated (0.17% VS 2.71%, P=0.001; 0.17% VS 2.37%, P=0.010, respectively). The levels of TRACP-5b and CTX in the newly diagnosed patients were higher than the normal controls (P=0.014, P=0.037) and remission patients (P=0.025, P=0.003), and they were significantly higher in stage B than the normal controls (P=0.015, P=0.002). However, PINP and OCN levels had no significantly changes in different stages.
Conclusion
In conclusion, abnormal circulating OBPs and OCPs were found earlier before X-ray in MM and still existed in remission patients, indicating that they maybe novel predictive markers for early diagnosing and monitoring bone disease.
Session topic: E-poster
Keyword(s): Myeloma, Osteoblast, Osteoclast
{{ help_message }}
{{filter}}